Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.99 | -0.36 | 0.23 |
| FCF Yield | -10.30% | -8.86% | -10.72% | -11.75% |
| EV / EBITDA | 8.28 | -13.25 | -10.20 | -9.84 |
| Quality | ||||
| ROIC | 35.92% | -60.06% | -55.14% | -33.89% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -0.82 | 0.63 | 0.63 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 103.54% | 16.27% | 5.04% | -6.45% |
| Free Cash Flow Growth | -73.65% | 8.63% | 3.10% | 26.61% |
| Safety | ||||
| Net Debt / EBITDA | 1.68 | -3.56 | -2.42 | -1.54 |
| Interest Coverage | 6.01 | -2.79 | -3.05 | -4.23 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 301.31 | 101.96 | 116.44 | 82.86 |